Michael Culler Email and Phone Number
Michael Culler work email
- Valid
- Valid
Michael Culler personal email
Michael Culler phone numbers
Chief Scientific Officer for Amolyt Pharma. Scientific founder and Chairman of the Scientific Advisory Board for Tiburio Therapeutics. Co-founder of Rhythm Pharmaceuticals. Led the pre-clinical programs that produced the key development assets for Rhythm (relamorelin and setmelanotide: Imcivree®), Radius Pharma (abaloparatide: Tymlos®) and Tiburio Therapeutics (TBR-760 and TBR-065). Former Vice President, Endocrinology Research for Ipsen. While at Ipsen, led programs in diverse endocrine/metabolic areas that resulted in six compounds reaching clinical development. Prior to joining industry, conducted basic research in neuroendocrine physiology as a staff scientist at the National Institutes of Health, and as a postdoctoral fellow at Tulane University School of Medicine. Internationally recognized expert in endocrinology, metabolic disorders, endocrine oncology, and peptide therapeutics, with over 200 publications and 22 patents. Member of the Prohibited List Expert Committee of the World Anti-Doping Agency (WADA)
Amolyt Pharma
View-
Chief Scientific OfficerAmolyt Pharma 2018 - PresentEcully, FrAlizé Pharma is specialized in developing innovative therapeutic peptides for the treatment of rare endocrine and metabolic diseases. Our portfolio includes a best-in-class parathyroid hormone (PTH) analog uniquely designed for the treatment of hypoparathyroidism, and a small peptide antagonist of the growth hormone receptor for the treatment of acromegaly.
-
Scientific Founder, And Chairman Of The Scientific Advisory BoardTiburio Therapeutics 2018 - PresentTiburio is dedicated to advancing novel treatments for serious neuroendocrine disorders such as non-functioning pituitary adenoma (NFPA). Tiburio is currently developing TBR-760, a dopamine-somatostatin chimeric compound, for the treatment of non-functioning pituitary adenoma (NFPA). Tiburio’s development stage pipeline also includes TBR-065, a novel therapy for other rare neuroendocrine diseases.
-
PresidentCuller Consulting, Llc 2017 - PresentProviding expert consultation for research, development, and related activities in endocrinology, neuroendocrinology, and metabolic disease for multiple biotechnology and large-pharma clients
-
Vice President, Endocrinology ResearchIpsen 1995 - 2017Boulogne Billancourt, FrVice President, Endocrinology Research (2008 - 2017)Senior Director and Head of Endocrinology Research (2002 - 2008)Director and Head of Biological Research (1995 - 2002)• Directed multiple, successful research programs in diverse endocrine/metabolic indications producing five compounds currently in or completing clinical development.• PTHrP Analog (BIM-44058: Abaloparatide) for Osteoporosis (Market Approval: Tymlos®)• GLP1 Analog (BIM-51077: Taspoglutide) for Diabetes (Phase III Clinical)• Ghrelin Analog (BIM-28131: Relamorelin) GI motility/Cachexia (Phase III Clinical)• MC4 Agonist (BIM-22493: Setmelanotide) Obesity/Diabetes (Market Approval: Imcivree®)• Somatostatin-Dopamine Chimeric Molecule (BIM-23B065) Pituitary Tumors (Phase I Clinical)• Successfully managed efforts, and delivered presentations to out-license assets for development, and to secure venture capital funding. Co-founded Rhythm Pharmaceuticals for development of relamorelin and setmelanotide.• Built and maintained extensive network of external academic and industry collaborators to accelerate programs by taking advantage of established models and expertise. Source of new targets, concepts and valuable opinions in diverse endocrine areas. -
Assistant Director, Endocrinology ResearchJohnson And Johnson Immunobiology Research Institute 1992 - 1995Research: Endocrine-immune interactions, hormonal basis of affective disorders, antisera and immunoassay development
-
Senior Research FellowNational Institute Of Environmental Health Sciences (Niehs) 1984 - 1992Research Triangle Park, Nc, UsResearch: Endocrine communication within hypothalamic-pituitary-gonadal axis, pulsatile hormone secretion, immunoneutralization of endogenous hormones, antisera and immunoassay development. -
Postdoctoral Fellow - NeuroendocrinologyTulane Medical Center 1981 - 1984Mentor: Dr. Akira ArimuraResearch: Design and development of bio- and immunoassays for target neuroendocrine factors. Member of team for isolation and characterization of novel brain hormones; successful isolation, sequencing and characterization of PACAP. Conducted research into intracellular mechanisms of hormone action.
Michael Culler Skills
Michael Culler Education Details
-
Tulane University School Of MedicineNeuroendocrinology -
Texas A&M UniversityEndocrine Physiology
-
University Of MarylandPhysiology
-
Hood CollegeBiology
Frequently Asked Questions about Michael Culler
What company does Michael Culler work for?
Michael Culler works for Amolyt Pharma
What is Michael Culler's role at the current company?
Michael Culler's current role is CSO for Amolyt Pharma. Scientific founder and Chairman, Scientific Advisory Board for Tiburio Therapeutics.
What is Michael Culler's email address?
Michael Culler's email address is mi****@****sen.com
What is Michael Culler's direct phone number?
Michael Culler's direct phone number is +39023*****
What schools did Michael Culler attend?
Michael Culler attended Tulane University School Of Medicine, Texas A&m University, University Of Maryland, Hood College.
What skills is Michael Culler known for?
Michael Culler has skills like Pharmaceutical Industry, Endocrinology, Biotechnology, Oncology, Clinical Development, Molecular Biology, Drug Development, Drug Discovery, Pharmacology, Clinical Trials, Cro.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial